Synthesis and DNA cleavage activity of a novel bleomycin A(5) glycoconjugate.
[structure in text] To explore the possibility of modifying bleomycin in a fashion that could alter its physiological distribution in a therapeutic setting, a new analogue of bleomycin has been prepared. This analogue is intended to target the asialoglycoprotein receptor on liver cells. Critically, despite the large C-substituent, the bleomycin conjugate was found to degrade DNA in the same fashion as bleomycin A(5) itself, and with only modestly decreased efficiency.
Choudhury
A K
AK
Department of Chemistry, University of Virginia, Charlottesville, Virginia 22901, USA.
Tao
Z F
ZF
Hecht
S M
SM
D001761:Bleomycin / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002384:Catalysis; D004247:DNA / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000166:cytology; D015394:Molecular Structure; D010957:Plasmids / Q000737:chemistry*; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured / Q000187:drug effects
C428263:bleomycin A5 glycoconjugate; D001761:Bleomycin; C025703:bleomycetin; D004247:DNA